Spots Global Cancer Trial Database for Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
Official Title: A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Study ID: NCT04887870
Study Description
Brief Summary: A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies
Detailed Description: Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that inhibits several closely related RTKs including the TAM family (Tyro3/Axl/MERTK), VEGFR2, KIT, and MET. The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beverly Hills Cancer Center, Beverly Hills, California, United States
Rocky Mountain Cancer Centers, Aurora, Colorado, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
University of Minnesota Health Clinics and Surgery Center, Minneapolis, Minnesota, United States
GU Research Network/Urology Cancer Center, Omaha, Nebraska, United States
New York Oncology Hematology, P.C., Clifton Park, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic, Columbus, Ohio, United States
Texas Oncology - Denison Cancer Center, Denison, Texas, United States
UT MD Anderson Cancer Center, Houston, Texas, United States
NEXT Oncology, San Antonio, Texas, United States
NEXT Virginia, Fairfax, Virginia, United States
Contact Details
Name: Ronald Shazer, MD
Affiliation: Mirati Therapeutics Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
